Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Melphalan in Higher Risk MDS and CMML
NCT00744536Phase 2Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Jan 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Sunnybrook Health Sciences Centre. Started Jan 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00744536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00744536.